Form 4 for STLN Starling Oncology, Inc.
Accepted 2023-03-21 00:00:00 ET · period of report 2023-03-17 · accession 0001628280-23-008827 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-21 | 2023-03-17 | STLN | Pacala Mark L | Dir | A - Grant | $0.00 | +6,562 | 88.4K | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-03-17 | A | A | 6,562 | $0.00 | 88,399 | D | — | — | (F1) Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date. |